Zimmer Biomet Guides FY26 Adj EPS to $8.47-$8.49, Above Consensus
ZBH sits 23% above its 52-week low of $79.12.
Summary
Zimmer Biomet issued FY26 adjusted EPS guidance of $8.47-$8.49, a narrow range that likely exceeds Street expectations. This follows the Q2 2026 earnings release today, which showed 4.8% reported sales growth and raised full-year revenue and adjusted EPS outlooks. The company has been actively buying back shares, targeting up to $1 billion in repurchases this year, which supports per-share figures. The guidance signals management's confidence in sustained demand and margin execution.
At the time of this announcement, ZBH was trading at $97.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $18.5B. The 52-week trading range was $79.12 to $108.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.